This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Neurodevelopment After Early Iron Supplementation

This study has been completed.
Information provided by:
University of Ulm Identifier:
First received: April 6, 2007
Last updated: NA
Last verified: April 2007
History: No changes posted

Background: Iron deficiency in early childhood may impair neurodevelopment.

Aim: To examine whether early iron supplementation improved neurodevelopment in preterm infants.

Method: Children who participated in a clinical trial of iron supplementation were invited for a neurodevelopmental follow-up examination at the time of school entry.

Condition Intervention
Iron Deficiency Anemia of Prematurity Neurodevelopmental Delay Drug: Oral administration of ferrous sulphate

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single
Primary Purpose: Prevention
Official Title: Early Versus Late Enteral Iron Supplementation in Infants With a Birth Weight of Less Than 1301g – Neurocognitive Development at 5.3 Years Corrected Age

Resource links provided by NLM:

Further study details as provided by University of Ulm:

Primary Outcome Measures:
  • ferritin at 61 days of life
  • the number of infants who fulfilled the criteria of ID at any time throughout the study.

Secondary Outcome Measures:
  • Neurological Status
  • Mental Processing Composite (Kaufmann Assessment Battery for Children)
  • Disability Status
  • Behavioural Problems

Estimated Enrollment: 204
Study Start Date: April 2002
Study Completion Date: December 2005
Detailed Description:

Children with a birth weight of < 1301g who participated in a randomized controlled trial of early versus late enteral iron supplementation were evaluated applying a standardized neurological evaluation, the Kaufmann Assessment Battery for Children, and the Gross Motor Function Classification Scale (GMFCS) at the age of school entry.

Severe disability was defined as any of the following: any abnormal neurological examination associated with a severely impaired mobility (GMFCS>1), severe cognitive impairment (mental processing composite (MPC) <51), hearing loss requiring amplification, or blindness. The absence of disability was defined as normal neurological examination, normal mobility (GMFCS=0), and normal cognitive development (MPC>85) and the absence of any severe hearing and visual impairment.


Ages Eligible for Study:   4 Years to 7 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • inborn infants with a birth weight of <1301g admitted between June 1996 and June 1999

Exclusion Criteria:

  • major anomalies, hemolytic disease, twin-to-twin transfusion syndrome, missing parental consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00457990

University Children's Hospital
Ulm, Germany, 89070
Sponsors and Collaborators
University of Ulm
Principal Investigator: Axel R Franz, MD University of Ulm
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00457990     History of Changes
Other Study ID Numbers: UL-NEO-IRON-2
Study First Received: April 6, 2007
Last Updated: April 6, 2007

Keywords provided by University of Ulm:
Neurocognitive outcome
preterm infant
very low birth weight
iron deficiency
iron supplementation

Additional relevant MeSH terms:
Anemia, Iron-Deficiency
Anemia, Hypochromic
Hematologic Diseases
Iron Metabolism Disorders
Metabolic Diseases
Trace Elements
Growth Substances
Physiological Effects of Drugs processed this record on August 21, 2017